The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | The role of venetoclax in previously treated WM including BTK inhibitor-exposed patients
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment options for patients with Waldenström’s macroglobulinemia (WM) who progress after standard chemotherapy and/or Bruton’s tyrosine kinase (BTK) inhibitors, highlighting the role of venetoclax in this patient population. Dr Castillo shares the findings from a study which evaluated the efficacy of venetoclax in previously-treated WM patients, including the progression-free survival (PFS) and very good partial response (VGPR) observed. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting fees or research funds from Abbvie, AstraZeneca, BeiGene, Casma, Cellectar, Janssen, Pharmcyclics, Roche, TG Therapeutics.
